 |
20 Diseases |  |
29 Trials |
|
29 Trials |  |
1253 News |  |
| «12...678910111213141516...1920» |
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance hemodialysis. (Pubmed Central) - Jun 22, 2021
Sofosbuvir plus Velpatasvir fixed-dose combination is safe and effective in treating CHC in patients with ESRD on MHD.
- || ribavirin / Generic mfg.
Clinical, Journal: Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis. (Pubmed Central) - Jun 22, 2021
Hence, sofosbuvir can be safely used in patients undergoing hemodialysis. Key Words: Sofosbuvir, Hemodialysis, Hepatitis C.
- ||| sofosbuvir/velpatasvir / Generic mfg.
FDA event: The @US_FDA approves new formulation of #Epclusa @GileadSciences for chronic hepatitis C virus in children as young as 3 years of age. https://t.co/tVniPHTsnH @KarenMurrayMD @CleClinicKids #hepatitis #hepatitisc #HCV #FDA (Twitter) - Jun 21, 2021
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal, Real-world evidence: Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan. (Pubmed Central) - Jun 16, 2021
Key Words: Sofosbuvir, Hemodialysis, Hepatitis C. SOF/VEL treatment is well tolerated and achieves high SVR rates for patients of Taiwanese ethnicity with HCV, regardless of cirrhosis status.
- || Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Clinical, Review, Journal: Breakthroughs and challenges in the management of pediatric viral hepatitis. (Pubmed Central) - Jun 8, 2021
Anti-HBV investigational compounds are reviewed in light of the pathophysiology in the pediatric population, including capsid assembly modulators, antigen secretion inhibitors, silencing RNAs, and immune modifiers. Recommendations for screening and management of immunosuppressed children or those with other risk factors or comorbidities are also summarized.
- | sofosbuvir/velpatasvir / Generic mfg.
Journal: Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy. (Pubmed Central) - Jun 5, 2021
Recommendations for screening and management of immunosuppressed children or those with other risk factors or comorbidities are also summarized. SOF/VEL given as DOT along with OAT in PWIDs at high risk of non-adherence to antiviral therapy including those with ongoing intravenous drug use resulted in excellent SVR rates similar to patients with presumed "excellent compliance" under standard drug intake.
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Journal: Pharmacotherapy Profiles in People with Opioid Use Disorders: Considerations for Relevant Drug-Drug Interactions with Antiviral Treatments for Hepatitis C. (Pubmed Central) - Jun 3, 2021
Contraindications (i.e., DDIs precluding HCV therapy) were infrequent (0.4-2.5% of co-medications); potential DDIs with HCV therapies were shown for 13-19% of co-medications, namely for specific substances including some analgesics, antipsychotics, anticoagulants, lipid lowering drugs and steroids. In conclusion, concomitant pharmacotherapy is common and clinically relevant when treating HCV infection in PWID.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] High HCV cure rates in C-FREE, first community-based study offering testing and treatment of viral hepatitis and HIV among people who use drugs and their partners in Thailand () - May 27, 2021 - Abstract #IASHIV2021IAS_HIV_592;
Community-based HCV treatment with sofosbuvir/velpatasvir for PWUD in Thailand, within harm reduction settings, is safe and highly effective. National programs should urgently integrate community-based HIV and HBV/HCV test and treat services as standard of care for drug-using populations to decrease morbidity and onward transmission of these infections.
- Daklinza (daclatasvir) / BMS
[VIRTUAL] Uptake of Direct Acting Antivirals for treatment of hepatitis C in human immunodeficiency virus/ hepatits C co-infected children and adolescents in the Russian Federation (Poster area) - May 26, 2021 - Abstract #EASLILC2021EASL_ILC_1465;
Most of those in care at responding clinics were treated soon after approval of pangenotypic formulations. Access to treatment for younger children needs expansion as DAAs are licensed for these age groups.
- || Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Clinical, Journal: Clinical Experience of Patients With Hepatitis C Treated With Direct-Acting Antivirals After Heart Transplantation. (Pubmed Central) - May 25, 2021
Patients who cannot afford branded drugs because of their prices can use generic drugs as an alternative. Drug interactions must be surveyed during DAA treatment.
- |||| sofosbuvir/velpatasvir / Generic mfg.
Clinical: No major DDA using sofosbuvir/velpatasvir with first-line systemic therapy detected. @NDP1001 do you have a preferred regimen? #HCC #livertwitter #DDW2021 (Twitter) - May 22, 2021
- || voxilaprevir (GS-9857) / Gilead
Clinical, Journal: VIROLOGICAL PATTERNS OF HCV-PATIENTS WITH FAILURE TO THE CURRENT GENERATION DIRECTLY ACTING ANTIVIRALS. (Pubmed Central) - May 20, 2021
Drug interactions must be surveyed during DAA treatment. To our knowledge, this is one of the first real-life studies describing patients who failed the current generation DAAs; the prevalence of RAS was different according to the DAA regimen used, and the efficacy of re-treatment was high.
- ribavirin / Generic mfg.
[VIRTUAL] Outcomes of Hepatitis C Nucleic Acid Testing Positive Donors in Aviremic Recipients With Delayed Direct-Acting Antiviral Initiation () - May 18, 2021 - Abstract #ATC2021ATC_2334;
This study adds to the paucity of literature describing the delayed start of DAA therapy for donor transmitted HCV in SOT and assuages the concerns of HCV sequelae by demonstrating efficacy via high SVR12 rates and no fibrosing cholestatic cirrhosis. This delay in DAA initiation shifts the financial burden to 3rd party insurances without compromising transplant related outcomes.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants () - May 18, 2021 - Abstract #ATC2021ATC_2330;
This paper describes extremely low transmission rate with a seven-day peri-operative DAA regimen. Compared with a matched HCV negative kidney transplant recipient cohort, D+/R- transplants had reduced wait times and comparable short-term kidney function outcomes.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
[VIRTUAL] Comprehensive Utilization of HCV Viremic and Non-Viremic Donor Livers and Kidneys into HCV-negative Patients () - May 18, 2021 - Abstract #ATC2021ATC_2237;
100% of HCV-negative patients transplanted with HCV NAT+ organs achieved SVR. We propose that transplantation of HCV viremic and non-viremic liver and kidneys into HCV-negative patients become standard of care.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
[VIRTUAL] Evaluation and Experience with Hepatitis C Positive to Negative PancreasTransplantation () - May 18, 2021 - Abstract #ATC2021ATC_2009;
Hepatitis C negative kidney-pancreas transplant recipients can safely receive HCV(+) grafts and be cured of HCV post-transplant similar to other organ groups. Benefits in terms of waitlist time reduction and long-term outcomes will need to be studied further
- Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
[VIRTUAL] Successful Single-Center Experience Using HCV+ Organs for Single and Dual-Organ Transplantation () - May 18, 2021 - Abstract #ATC2021ATC_1837;
We report successful single-center experience using HCV+ organs for both single and dual solid organ transplant. As experience using such organs for transplant continues to increase and long term follow-up is obtained, HCV+ donors may be routinely used to increase the organ donor pool.
- | daclatasvir/asunaprevir (BMS-60032/BMS-790052) / BMS
Journal, HEOR: Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China. (Pubmed Central) - May 15, 2021
Compared with other oral DAA agents, SOF/VEL treatment was not the most cost-effectiveness option for patients with chronic HCV GT1b in China. Lower the price of SOF/VEL will make it cost-effective while simplifying treatment and achieving the goal of HCV elimination.
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Clinical, Journal: Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection. (Pubmed Central) - May 15, 2021
Approximately on third of patients with CHC are concomitantly treated with CV drugs. SOF/VEL may have fewer DIs with CV drugs than other pDAAs.
- | Sovaldi (sofosbuvir) / Gilead
FDA event, Journal: Simultaneous spectrophotometric quantitative analysis of velpatasvir and sofosbuvir in recently approved FDA pharmaceutical preparation using artificial neural networks and genetic algorithm artificial neural networks. (Pubmed Central) - May 15, 2021
The developed models were successfully applied to the quantitative analysis of the two drugs in Epclusa® tablets. The results were statistically compared with another published quantitative analytical method with no significant difference by applying Student t-test and variance ratio F-test.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Application of different chemometric assisted models for spectrophotometric quantitative analysis of velpatasvir and sofosbuvir. (Pubmed Central) - May 15, 2021
Statistically comparative analysis for the obtained models results with another published capillary electrophoresis quantitative analytical method was performed. It is noteworthy mentioning that there was no significant difference between the proposed models and the published method with respect to the accepted statistical parameters.
- ||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion, Enrollment change: A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic (clinicaltrials.gov) - May 13, 2021
P4, N=11, Completed, Sponsor: Community Research Initiative of New England
It is noteworthy mentioning that there was no significant difference between the proposed models and the published method with respect to the accepted statistical parameters. Active, not recruiting --> Completed | N=20 --> 11
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study. (Pubmed Central) - May 6, 2021
In this study, the authors report the case of a patient diagnosed with hepatitis C virus who was treated with sofosbuvir-velpatasvir (400/100 mg). As the patient was unable to swallow whole tablets, therapeutic drug monitoring was performed to evaluate the effect of crushing sofosbuvir-velpatasvir tablets on drug absorption and global exposure.
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed: Expanding the Pool in Lung Transplantation (clinicaltrials.gov) - May 5, 2021
P1, N=20, Active, not recruiting, Sponsor: Pablo Sanchez
As the patient was unable to swallow whole tablets, therapeutic drug monitoring was performed to evaluate the effect of crushing sofosbuvir-velpatasvir tablets on drug absorption and global exposure. Recruiting --> Active, not recruiting
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Review, Journal: Hepatitis C: A Pharmacological Therapeutic Update. (Pubmed Central) - May 1, 2021
Subsequently, phase III studies have shown they were effective for previously treated or compensated cirrhotic patients that previously had more complex treatment regimens. (4) These results suppose a simplification in Hepatitis C therapeutic approach, and open new study possibilities.
- | ribavirin / Generic mfg.
Journal: Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy. (Pubmed Central) - Apr 29, 2021
This study demonstrated high adherence to once- and twice-daily HCV DAA therapy among people with recent injecting drug use or were currently receiving OAT. The levels of non-adherence described did not impact treatment outcomes, suggesting forgiveness to non-adherence.
- | sofosbuvir/velpatasvir / Generic mfg.
Journal: Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. (Pubmed Central) - Apr 28, 2021
P=N/A
The levels of non-adherence described did not impact treatment outcomes, suggesting forgiveness to non-adherence. The ANCHOR study demonstrates high uptake of buprenorphine collocated with HCV treatment, and shows that concurrent initiation of OAT with HCV treatment can result in high rates of SVR while reducing risks associated with drug use.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
[VIRTUAL] HEPATITIS C TREATMENT: DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS BASED ON THE SIMPLIFIED TREATMENT ALGORITHM () - Apr 11, 2021 - Abstract #AMCP2021AMCP_35;
HCV patients initiating SOF/VEL or GLE/ PIB via the simplified algorithm had lower comorbidity burden. Initial prescriptions and baseline encounters were drawn from a mix of specialists and non-specialists, which may indicate that more patients are able to be treated by a broader range of physicians.
- sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
[VIRTUAL] Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-December 2020 (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_1235;
Georgia has made substantial progress towards elimin- ating hepatitis C, with over 40% of personswith chronic HCV infection identified and cured. Efforts to identify and link to care persons with HCV infection, ensure SVR testing and implement prevention interventions are needed to achieve the elimination goals.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] FULL DOSE SOFOSBUVIR - VELPATASVIR IN CHRONIC HEPATITIS C IN PATIENTS WITH END STAGE RENAL DISEASE. (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_1234;
Efforts to identify and link to care persons with HCV infection, ensure SVR testing and implement prevention interventions are needed to achieve the elimination goals. We conclude that treatment with sofosbuvir-velpatasvir is a safe and effective treatment option in HCV infection in end stage renal disease.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
[VIRTUAL] Frequency and impact of potential multiple drug-drug interactions (DDIs) associated with pangenotypic direct-acting antivirals in patients receiving opioid substitution therapy (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_1228;
Compared to SOF/VEL, GLE/PIB is more frequently associated with potential multiple DDI in this population. Since the relevance of clinical outcomes may differ, possible consequences of DDI should be evaluated carefully prior to initiation of pDAA treatment in OST pts.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
[VIRTUAL] Risk of multiple drug-drug interactions (DDIs) in HCV patients receiving pangenotypic DAAs (pDAAs): A complex drug interaction scenario first time evaluated in German patients (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_1226;
In Germany, the percentage of HCV patients treatedwith pDAAs and ≥2 comedications showing risk of DDIs is 3.5%. The most frequent outcome resulted from the multiple DDI context was a decrease in the DAA, having similar risk both pDAA.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] 12 weeks treatment of Sofosbuvir/Velpatasvir in HCV negative recipients receiving renal transplantation from HCV positive donors (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_1202;
The most frequent outcome resulted from the multiple DDI context was a decrease in the DAA, having similar risk both pDAA. Sofosbuvir/Velpatasvir prophylaxis treatment was effective and safe in HCV uninfected recipients who received renal transplantation from HCV positive donors.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] Concordance of SVR 4-12-24 timepoints in an era of reduced sustained virologic response (SVR) determination (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_1185;
This early time point to confirm HCV may be important when monitoring a vulnerable population at high risk to be lost to follow-up. These data support minimal monitoring of HCV treatment and follow-up, and the EASL guidance that testing for SVR can be omitted in certain patients without compromising the treatment paradigm.
- ribavirin / Generic mfg.
[VIRTUAL] Telemedicine improve HCV elimination among Italian people who use drugs: an innovative therapeutic model to increase the adherence to treatment into addiction care centers. (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_987;
We obtained a high SVR12 (98, 6%), providing a complete hepatologic assessment within addiction care center, tailoring the drug administration and performing a remote hepato- logic stewardship. Our therapeutic model should improve the time to treat and the adherence to treatment in PWUDs.
- Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date: SHELTER: Transplanting Hepatitis C Lungs Into Negative Lung Recipients (clinicaltrials.gov) - Apr 8, 2021
P1/2, N=10, Active, not recruiting, Sponsor: University of Pennsylvania
Our therapeutic model should improve the time to treat and the adherence to treatment in PWUDs. Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Enrollment status: Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant (clinicaltrials.gov) - Apr 8, 2021
P4, N=25, Enrolling by invitation, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021 Recruiting --> Enrolling by invitation
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] SPONTANEOUS HBV REMISSION AFTER HBV REACTIVATION FOLLOWING TREATMENT WITH SOFOSBUVIR AND VELPATASVIR IN A PATIENT WITH HCV AND HBV CO-INFECTION: CASE REPORT () - Mar 25, 2021 - Abstract #CDDW2021CDDW_304;
The significance of this case is to illustrate HBV reactivation following treatment of HCV with DAAs may not necessitate immediate treatment, especially if there are no signs of flare. There have been similar reported cases, but larger prospective studies are required to determine the appropriate clinical context where monitoring may be acceptable instead of immediate treatment.
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Clinical, Journal: Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure. (Pubmed Central) - Mar 20, 2021
There have been similar reported cases, but larger prospective studies are required to determine the appropriate clinical context where monitoring may be acceptable instead of immediate treatment. SOF/VEL/VOX is an effective and safe retreatment for HCV patients failing a previous DAA course in a real-life setting.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] A SIMPLE AND SAFE APPROACH TO HCV TREATMENT: FINDINGS FROM THE A5360 (MINMON) TRIAL () - Mar 18, 2021 - Abstract #CROI2021CROI_324;
In a diverse, global patient population, the MINMON approach to HCV treatment delivery was safe and achieved SVR comparable to current standards. Wider adoption of this approach coupled with innovative casefinding strategies may facilitate HCV elimination while minimizing in-person appointments and resource use.
- aspirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] VARIABLES INFLUENCING MORTALITY IN CHRONIC HEPATITIS C PATIENTS WITH HEPATOCELLULAR CARCINOMA: A SINGLE CENTER EXPERIENCE (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_4028;
In 2019, the State of Louisiana had made generic sofosbuvir/velpatasvir available to the public at a minimal cost. The impact of the Introduction: of generic DAAs on overall outcomes in patients with both HCV and HCC is currently underway at our institution.
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study. (Pubmed Central) - Mar 9, 2021
P=N/A
Virus sequencing did not identify baseline or treatment emergent resistance associated substitutions. Real-time mathematical modeling of early HCV kinetics can be utilized for shortening DAAs duration in approximately 40% of patients without compromising treatment efficacy.Clinical trial registration: ClinicalTrials.gov Identifier: NCT03603327.
- || pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
Clinical, Review, Journal: Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines. (Pubmed Central) - Mar 6, 2021
Our review shows that many countries have no national guidance on HCV testing and treatment in children and adolescents. It highlights the urgent need for advocacy and updated policies and guidelines specific for children and adolescents.
- || Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Clinical, Journal: Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir/pibrentasvir may identify patients for ultra-short treatment duration. (Pubmed Central) - Mar 5, 2021
In the current study modeling HCV kinetics in 44 cirrhotic and non-cirrhotic patients predicts that P/G treatment might have been reduced to 4, 6 and 7 weeks in 16%, 34% and 14% of patients, respectively. These results support the further evaluation of a modeling-based RGT approach under P/G therapy.
- || sofosbuvir/velpatasvir / Generic mfg.
Trial completion date, Trial primary completion date: THINKER-NEXT: A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients (clinicaltrials.gov) - Mar 3, 2021
P2, N=500, Not yet recruiting, Sponsor: University of Pennsylvania
These results support the further evaluation of a modeling-based RGT approach under P/G therapy. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2023
- || Sovaldi (sofosbuvir) / Gilead
Minou van Seyen is best knwon for her study in #sofosbuvir #velpatasvir and absorption under omeprazole ⬇️low absorption of #VEL/SOF with #PPI ✅restored with a glass of @CocaCola @paulykwo @londoncpt @liverunitclinic @st_clin @CPACLab @GuidetoPHARM https://t.co/QrnC023CKW (Twitter) - Feb 23, 2021
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Trial completion date, Trial primary completion date: TEMPO: A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams (clinicaltrials.gov) - Feb 23, 2021
P=N/A, N=300, Recruiting, Sponsor: Kirby Institute
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Nov 2020 --> Dec 2022 | Trial primary completion date: Nov 2020 --> Dec 2021
- || Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Use of sofosbuvir-based regimens in the treatment of adolescents and children with chronic hepatitis C (Pubmed Central) - Feb 14, 2021
Available clinical trial data show that sofosbuvir with ribavirin and ledipasvir/sofosbuvir are highly efficacious and safe in CHC patients aged 3-17 years old; therefore, they can meet the unmet medical needs of adolescents and children with CHC in China. Furthermore, the pan-genotypic sofosbuvir/velpatasvir is being investigated in adolescents and children with CHC, which is expected to make the treatment in such patients more convenient upon approval.
- || Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie, voxilaprevir (GS-9857) / Gilead
Clinical, Journal: Two case reports of chronic hepatitis C retreatment (Pubmed Central) - Feb 11, 2021
Two patients, one originally treated with dasabuvir/ombitasvir/paritaprevir/ritonavir and the other with glecaprevir/pibrentasvir, received a triple combination of sofosbuvir, velpatasvir and voxilaprevir for 12 weeks. Following the retreatment, both patients were permanently virus-free.
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed, Trial completion date: Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in Brazil (clinicaltrials.gov) - Feb 11, 2021
P=N/A, N=144, Active, not recruiting, Sponsor: Hospital de Clinicas de Porto Alegre
Following the retreatment, both patients were permanently virus-free. Recruiting --> Active, not recruiting | Trial completion date: Mar 2021 --> Jun 2021